Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + fruquintinib + short-course radiotherapy
- Development stage
- Unknown
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
toripalimab + fruquintinib + short-course radiotherapy is a neoadjuvant combination therapy regimen being investigated for the treatment of locally advanced rectal cancer (LARC). The regimen consists of toripalimab, a humanized IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor; fruquintinib, a highly selective oral tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3; and short-course radiotherapy (SCRT). This combination aims to enhance anti-tumor activity through the synergistic effects of immune checkpoint blockade, inhibition of tumor angiogenesis, and radiation-induced immunogenic cell death. The regimen is currently being evaluated in a Phase II clinical trial led by West China Hospital of Sichuan University to assess its efficacy and safety in achieving pathological complete response in patients with LARC.
- Other names
- toripalimab-West China Hospital-rectal cancerFruquintinib combined with Toripalimab and SRT in Neoadjuvant Therapy for Locally Advanced Rectal Cancer
02
Targets
VEGFR4 (Vascular endothelial growth factor Receptor-3)PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on toripalimab + fruquintinib + short-course radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + fruquintinib + short-course radiotherapy.